The amount of Aminopterin excreted during treatment with this antagonist has been measured in 9 leukemia patients. It was found that considerable although variable amounts were retained in the body and that the smallest amounts were excreted by patients with chronic granulocytic leukemia. Urinary excretion of Aminopterin continued at a significant level for a period of at least six days after a course of therapy.

Following Aminopterin therapy, there was an increase in folic acid excretion as compared to the excretion of this vitamin prior to antagonist administration.

These data suggest that there is a metabolic displacement of folic acid by Aminopterin.

This content is only available as a PDF.
© 1952 by American Society of Hematology, Inc.
1952
Sign in via your Institution